Genotyping and drug susceptibility profiling of Prototheca sp. strains isolated from cases of protothecosis in dogs
2025

Genotyping and Drug Resistance in Prototheca Strains from Dogs

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): Angelika Proskurnicka, Mateusz Iskra, Sylwia Wronka, Zofia Bakuła, Patrizia Danesi, Marconi Rodrigues de Farias, Fábio Vinícius Ramos Portilho, Márcio Garcia Ribeiro, Uwe Rösler, Rui Kano, Richard Malik, Tomasz Jagielski

Primary Institution: Department of Medical Microbiology, Institute of Microbiology, Faculty of Biology University of Warsaw

Hypothesis

To identify species and drug susceptibility profiles of an international collection of Prototheca strains isolated from cases of protothecosis in dogs.

Conclusion

The study identifies P. bovis as the most common species causing protothecosis in dogs and suggests that efinaconazole could be a potential treatment.

Supporting Evidence

  • 75% of the cases were caused by Prototheca bovis.
  • Efinaconazole was the most potent drug tested with a median MIC and MAC of 0.125 mg/L.
  • Fluconazole showed the lowest activity with MIC and MAC medians of 48 mg/L and 64 mg/L.

Takeaway

This study looked at a type of algae that can make dogs sick and found that one type is the most common cause of the illness. A new medicine might help treat it.

Methodology

Retrospective study using molecular typing and drug susceptibility testing on 28 Prototheca strains from dogs in 6 countries.

Limitations

The study is limited to a small number of strains and may not represent all cases of protothecosis in dogs.

Participant Demographics

Strains were isolated from dogs in 6 countries: Germany, Brazil, Italy, Australia, Japan, and the United Kingdom.

Digital Object Identifier (DOI)

10.1111/jvim.17173

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication